Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.62 -6.4%	$14.25	$7.05 ▼ $17.15	$354.12M	0.37	56,419 shs	108,267 shs
CLYM Climb Bio	$1.26	$1.25	$1.05 ▼ $9.21	$85.14M	-0.13	353,630 shs	262,575 shs
PRTA Prothena	$6.52 +3.7%	$6.27	$4.32 ▼ $25.42	$338.57M	0.01	801,106 shs	1.02 million shs
SNDL SNDL	$1.38 +11.3%	$1.30	$1.15 ▼ $2.40	$325.84M	3.4	1.96 million shs	4.42 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	+2.66%	+15.30%	-15.69%	+20.23%	+45.21%
CLYM Climb Bio	-1.56%	+1.61%	-9.35%	+11.50%	+125,999,900.00%
PRTA Prothena	-2.78%	+3.62%	+16.27%	-39.98%	-68.95%
SNDL SNDL	-2.75%	+2.48%	-6.06%	-2.36%	-36.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.1412 of 5 stars	3.6	2.0	3.1	0.8	0.0
CLYM Climb Bio	2.6249 of 5 stars	3.6	0.0	0.6	2.5	1.3
PRTA Prothena	3.0398 of 5 stars	4.2	2.0	1.0	1.7	1.3
SNDL SNDL	3.5078 of 5 stars	3.5	5.0	1.4	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.20	Buy	$23.83	88.85% Upside
CLYM Climb Bio	3.25	Buy	$9.00	614.29% Upside
PRTA Prothena	2.33	Hold	$31.50	383.13% Upside
SNDL SNDL	3.00	Buy	$3.63	162.68% Upside

Current Analyst Ratings Breakdown

Latest CLYM, PRTA, BNTC, and SNDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	4,140.94	N/A	N/A	$4.68 per share	2.70
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
PRTA Prothena	$135.16M	2.60	N/A	N/A	$9.05 per share	0.72
SNDL SNDL	$671.81M	0.54	N/A	N/A	$3.15 per share	0.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/30/2025 (Estimated)

Latest CLYM, PRTA, BNTC, and SNDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CLYM Climb Bio	N/A	14.25	14.25
PRTA Prothena	N/A	9.00	9.00
SNDL SNDL	0.10	4.62	3.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CLYM Climb Bio	69.76%
PRTA Prothena	97.08%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CLYM Climb Bio	3.20%
PRTA Prothena	9.20%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CLYM Climb Bio	9	67.58 million	65.41 million	N/A
PRTA Prothena	130	53.83 million	48.88 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable

CLYM, PRTA, BNTC, and SNDL Headlines

Recent News About These Companies

Sundial Raises $23M to Redefine Data-informed Decisions with AI

July 8 at 10:27 AM | businesswire.com

3 Marijuana Stocks For The Investor To Consider Before A Recovery

July 7 at 9:21 AM | marijuanastocks.comM

SNDL (NASDAQ:SNDL) Trading 2% Higher - Here's What Happened

July 4, 2025 | marketbeat.com

SNDL Inc. Announces Virtual Annual and Special Shareholders Meeting for July 2025

June 20, 2025 | tipranks.com

3 Cannabis Stocks For Investors To Secure For Future Gains

June 20, 2025 | marijuanastocks.comM

1CM Receives Court Approval for Arrangement with SNDL Inc

June 18, 2025 | newsfilecorp.comN

1CM Inc. Gains Court Approval for SNDL Arrangement

June 18, 2025 | tipranks.com

HYTN Receives Initial International Purchase Order for GMP Vape Cartridges

June 11, 2025 | finance.yahoo.com

Marijuana Stocks To Watch With Strong Market Potential

June 6, 2025 | marijuanastocks.comM

1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court Order

May 20, 2025 | finance.yahoo.com

Canadian Securities Exchange Reports April 2025 Performance Figures

May 15, 2025 | finance.yahoo.com

SA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLI

May 5, 2025 | msn.com

SNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has Increased

May 5, 2025 | seekingalpha.com

SNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call Transcript

May 3, 2025 | insidermonkey.com

SNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 3, 2025 | finance.yahoo.com

3 Marijuana Stocks For The Long Term Investing

May 2, 2025 | marijuanastocks.comM

SNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market Review

May 2, 2025 | uk.finance.yahoo.com

These Cannabis Companies Are Repurchasing Shares

May 2, 2025 | newcannabisventures.comN

SNDL Inc. (SNDL) Q1 2025 Earnings Call Transcript

May 2, 2025 | seekingalpha.com

SNDL 1Q Loss Widens

May 2, 2025 | marketwatch.com

SNDL Inc. Earnings Call Highlights Growth and Challenges

May 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, PRTA, BNTC, and SNDL Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.62 -0.87 (-6.45%)

Closing price 04:00 PM Eastern

Extended Trading

$12.62 +0.01 (+0.04%)

As of 06:18 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Climb Bio NASDAQ:CLYM

$1.26 0.00 (0.00%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Prothena NASDAQ:PRTA

$6.52 +0.23 (+3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$6.43 -0.09 (-1.32%)

As of 06:37 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

SNDL NASDAQ:SNDL

$1.38 +0.14 (+11.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.37 -0.01 (-0.43%)

As of 07:59 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time